single10MG
Tesamorelin
10MG Protocol
Tesamorelin 10MG
Injection Freq.
Inject once daily
Cycle Sched.
12–26 weeks; clinical trials support up to 52 weeks with monitoring
Reconstitution
3.0 mL BAC water
Reduction in visceral adipose tissue reported after 3–6 months
Improved lipid profile
potential liver-fat reduction in NAFLD research
Potential cognitive benefits in older adults (research ongoing)
Benefits maintained with continuous use up to ~52 weeks (as described)
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–1 | 1 mg / 1000 mcg | 30 |
| 2 | Weeks 2+ | 2 mg / 2000 mcg | 60 |
Inject once daily
12–26 weeks; clinical trials support up to 52 weeks with monitoring
Tesamorelin is described as a synthetic analog of human growth-hormone–releasing hormone (GHRH). In the protocol, it binds pituitary GHRH receptors and triggers pulsatile endogenous growth hormone secretion, which then increases circulating IGF-1. This GH/IGF-1 cascade is presented as driving lipolysis (fat breakdown), supporting protein synthesis, and producing broader metabolic shifts. The page highlights clinical observations in HIV-associated lipodystrophy where daily tesamorelin use reduced visceral adipose tissue and improved lipid markers over months. It also notes ongoing research interest in liver-fat reduction in NAFLD and possible cognitive effects in older adults via partial restoration of age-related GH/IGF-1 declines. Because it elevates IGF-1, the protocol emphasizes monitoring considerations in research contexts. Overall, the mechanism is framed as upstream activation of the GH axis through physiologic, pulsatile stimulation rather than direct GH administration.
Injection-site reactions (redness/itching/pain/bruising)
Joint pain and muscle aches
Peripheral edema (mild swelling)
Carpal-tunnel–like symptoms (tingling/numbness
dose-dependent/reversible)
IGF-1 elevation requiring monitoring
small HbA1c increases reported
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)